Schizophrenia therapy - Eli Lilly
Latest Information Update: 29 Apr 2013
At a glance
- Originator Eli Lilly
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 17 Apr 2013 Discontinued - Phase-I for Schizophrenia in USA (unspecified route)
- 15 Apr 2009 Phase-I clinical trials in Schizophrenia in USA (unspecified route)